Table 1.

A: a Univariate analysis (ANOVA) results of integrin β1 in the primary tumor
Predictor		Integrin Beta 1
		N	Mean	Std Dev	p
Disease	No Met	99	24.752	20.550	<.0001
	Met	101	42.564	29.121
Age	Below median (<61)	103	35.029	26.824	0.4859
	Above median (>=61)	97	32.386	26.675
Sex	Female	71	36.683	28.620	0.2500
	Male	129	32.131	25.581
Site	1=OP	38	29.078	29.707	0.1183
	2=L	61	30.295	24.211
	3=OC	101	37.589	26.680
T	1	66	35.984	25.911	0.3679
	2	69	33.833	30.028
	3	29	36.862	30.106
	4	36	26.972	16.432
N	0	99	24.752	20.550	<.0001
	1	19	42.894	31.306
	2	74	42.472	28.476
	3	8	42.625	33.738
Radiation	No	72	31.840	24.416	0.4684
	Yes	123	34.707	27.781
Chemotherapy	No	175	32.757	26.236	0.2156
	Yes	23	40.043	28.013
	Missing	2
Differentiation	1=PD	36	32.180	30.088	0.3789
	2=MD	132	35.469	26.320
	3=WD	32	28.406	24.244
Smoking	No	30	34.866	29.765	0.9159
	Yes	158	34.300	26.308
	Missing	12
Stage	I	42	33.619	22.631	0.0001
	II	31	19.209	18.896
	III	29	24.482	25.392
	IV	98	41.142	28.336

B: Integrin β1 expression level by grading scale in the primary tumors
	None-Met		Met
Expression Level (%)	Number	%	Number	%
0–25	61	61.6	37	36.6
25–50	29	29.3	20	19.8
50–75	8	8.1	23	22.8
75–100	1	1.0	21	20.8

OP: Oropharynx L: Larynx OC: Oral cavity PD: Poorly differentiated MD: Moderately differentiated WD: Well differentiated

p<0.0001